Promimic AB (publ) (PRO.ST)
SEK 25.0
(0.4%)
SEK 25.0
(0.4%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -50.32 Million SEK | 14.42% |
| 2022 | -58.8 Million SEK | -589.98% |
| 2021 | -8.52 Million SEK | 65.04% |
| 2020 | -24.37 Million SEK | -120.05% |
| 2019 | -11.07 Million SEK | -5128.82% |
| 2018 | 220.31 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -37.98 Million SEK | 18.5% |
| 2024 Q1 | -46.6 Million SEK | 7.4% |
| 2023 Q2 | -55.12 Million SEK | 8.15% |
| 2023 FY | -50.32 Million SEK | 14.42% |
| 2023 Q4 | -50.32 Million SEK | 6.54% |
| 2023 Q3 | -53.84 Million SEK | 2.33% |
| 2023 Q1 | -60.02 Million SEK | -2.07% |
| 2022 Q2 | -74 Million SEK | -3885.14% |
| 2022 Q4 | -58.8 Million SEK | 4.73% |
| 2022 Q3 | -61.71 Million SEK | 16.6% |
| 2022 FY | -58.8 Million SEK | -589.98% |
| 2022 Q1 | -1.85 Million SEK | 78.21% |
| 2021 Q4 | -8.52 Million SEK | 31.07% |
| 2021 Q3 | -12.36 Million SEK | 25.83% |
| 2021 FY | -8.52 Million SEK | 65.04% |
| 2021 Q2 | -16.67 Million SEK | 17.55% |
| 2021 Q1 | -20.21 Million SEK | 0.0% |
| 2020 FY | -24.37 Million SEK | -120.05% |
| 2019 FY | -11.07 Million SEK | -5128.82% |
| 2018 FY | 220.31 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | -43.171% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 104.102% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 104.102% |
| Arcoma AB | -1.12 Million SEK | -4361.259% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 145.797% |
| BICO Group AB (publ) | 927.9 Million SEK | 105.423% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 139.071% |
| CellaVision AB (publ) | -56.94 Million SEK | 11.624% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | -238.26% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | -495.171% |
| C-Rad AB (publ) | -127.6 Million SEK | 60.562% |
| Duearity AB (publ) | 10.23 Million SEK | 591.868% |
| Dignitana AB (publ) | 13.07 Million SEK | 484.821% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 4.51% |
| Getinge AB (publ) | 5.4 Billion SEK | 100.931% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | -43.562% |
| Iconovo AB (publ) | -10.75 Million SEK | -367.889% |
| Integrum AB (publ) | -10.47 Million SEK | -380.34% |
| Luxbright AB (publ) | -13.83 Million SEK | -263.777% |
| Mentice AB (publ) | -49.56 Million SEK | -1.531% |
| OssDsign AB (publ) | -162.78 Million SEK | 69.087% |
| Paxman AB (publ) | -11.41 Million SEK | -341.004% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 363.886% |
| SciBase Holding AB (publ) | -27.32 Million SEK | -84.171% |
| ScandiDos AB (publ) | -1.53 Million SEK | -3186.937% |
| Sectra AB (publ) | -772.85 Million SEK | 93.489% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 77.819% |
| Senzime AB (publ) | -139.54 Million SEK | 63.937% |
| SpectraCure AB (publ) | -50.23 Million SEK | -0.177% |
| Stille AB | -178.5 Million SEK | 71.808% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 104.098% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 76.556% |